Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

6.08
+0.36006.29%
Post-market: 6.380.3000+4.93%19:19 EST
Volume:997.55K
Turnover:5.95M
Market Cap:414.97M
PE:-2.98
High:6.31
Open:5.54
Low:5.54
Close:5.72
Loading ...

EyePoint Announces Participation at Upcoming Investor Conferences

GlobeNewswire
·
Yesterday

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Simply Wall St.
·
27 Feb

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

GlobeNewswire
·
26 Feb

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
25 Feb

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
17 Feb

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
17 Feb

Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?

Zacks
·
11 Feb

EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
06 Feb

BUZZ-EyePoint Pharma rises on eye disease drug trial data

Reuters
·
05 Feb

EyePoint Pharmaceuticals: An Undervalued Opportunity Amid Market Overreaction and Financing Concerns

TIPRANKS
·
05 Feb

EyePoint's Phase 2 Trial of Duravyu to Treat Diabetic Macular Edema Meets Endpoints; Shares Still Slump Pre-Bell

MT Newswires Live
·
05 Feb

Collegium Pharmaceutical Expands Board with Nancy Lurker

TIPRANKS
·
05 Feb

Collegium appoints Nancy Lurker to board of directors

TIPRANKS
·
05 Feb

Top Premarket Decliners

MT Newswires Live
·
05 Feb

EyePoint announces Phase 2 VERONA trial met primary endpoint

TIPRANKS
·
05 Feb

EyePoint Announces Positive Six-Month Results for the Phase 2 Verona Clinical Trial of Duravyu™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

THOMSON REUTERS
·
05 Feb